Related Experiment Video
Updated: Mar 13, 2026

Evaluation of Exon Inclusion Induced by Splice Switching Antisense Oligonucleotides in SMA Patient Fibroblasts
Published on: May 11, 2018
Perceived Impact on the Daily Lives of Patients With Spinal Muscular Atrophy Treated With Nusinersen: A Natural
Sandra Castellar-Leones1,2, Edicson Ruiz-Ospina1,2, Cristian Correa-Arrieta2
1Department of Physical Medicine and Rehabilitation, School of Medicine, Universidad Nacional de Colombia.
Objective:
Spinal muscular atrophy (SMA) is a rare neuromuscular disorder caused by SMN1 mutations, leading to progressive muscle weakness. Although nusinersen improves motor function, its broader impact on daily life remains insufficiently understood. This study explored caregivers' perceptions of nusinersen treatment and identified themes reflecting its influence on everyday functioning.
Methods:
An observational study included 23 children with SMA (10 type 2, 7 type 3, 6 type 1) treated with nusinersen for up to 36 months. The mean age at interview was 6.3 years (SD: 2.3). Caregivers completed a semistructured questionnaire with closed and open-ended items. Narrative responses were analyzed using natural language processing (NLP) and topic modeling to identify recurring patterns.
Results:
Caregivers reported consistent positive effects. NLP identified 3 thematic clusters: functional and daily progress (34.9%), global improvement and quality of life (33.6%), and hospitalization and physical recovery (31.5%). Reported benefits included improved swallowing, easier breathing, fewer hospitalizations, increased independence, and enhanced mood. Families emphasized reduced stress and improved family dynamics.
Conclusions:
Caregivers perceive nusinersen as providing meaningful improvements in daily functioning beyond motor outcomes. Incorporating caregiver-reported insights through NLP may enrich treatment evaluation and support holistic, patient-centered and family-centered care in SMA.
More Related Videos
06:51Systemic Delivery of MicroRNA Using Recombinant Adeno-associated Virus Serotype 9 to Treat Neuromuscular Diseases in Rodents
Published on: August 10, 2018
05:16Characterizing Exon Skipping Efficiency in DMD Patient Samples in Clinical Trials of Antisense Oligonucleotides
Published on: May 7, 2020
Related Concept Videos
Myasthenia Gravis: Overview and Treatment
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
Parkinson's Disease: Treatment
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Satellite Stem Cells and Muscular Dystrophy
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
Therapeutic Drug Monitoring: Affecting Factors
Nephrotic Syndrome III : Nursing Management